NC
CBAY

Nexthera Capital’s Cymabay Therapeutics CBAY Stock Holding History

Nexthera Capital’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-210,257
Closed -$2.79M – 32
2019
Q1 		$2.79M Sell
210,257
-504,507
-71% -$5.37M 3.39% 11
2018
Q4 		$5.63M Sell
714,764
-193,900
-21% -$1.85M 2.32% 14
2018
Q3 		$10.1M Buy
908,664
+80,009
+10% +$994K 1.93% 15
2018
Q2 		$11.1M Sell
828,655
-24,031
-3% -$301K 1.72% 18
2018
Q1 		$11.1M Buy
852,686
+316,118
+59% +$3.93M 1.82% 19
2017
Q4 		$4.94M Buy
536,568
+521,568
+3,477% +$4.46M 0.91% 27
2017
Q3 		$121K Buy
+15,000
New +$101K 0.03% 38

Other funds holding CBAY

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return

Nexthera Capital's CBAY Position: Q2 2019 in Review

Nexthera Capital sold out of Cymabay Therapeutics (CBAY) in Q2 2019, closing a stake of 210,257 shares — an estimated $2.79M sold.

Nexthera Capital first reported a position in CBAY in Q3 2017 and held it in 7 quarters. The position peaked at $11.1M in Q2 2018. 133 funds tracked by Wall St. Rank hold CBAY as of Q2 2019.

  • Nexthera Capital reported no remaining Cymabay Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Nexthera Capital sold 210,257 Cymabay Therapeutics shares in Q2 2019, an estimated $2.79M.
  • Nexthera Capital first reported a position in Cymabay Therapeutics in Q3 2017 and held it in 7 quarters.
  • Nexthera Capital's Cymabay Therapeutics position peaked at $11.1M in Q2 2018.
  • 133 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q2 2019.

Based on Nexthera Capital's 13F filing for Q2 2019, filed 14 Aug 2019.